Carl L Gordon bought $15.0M of Scribe Therapeutics (SCTX)
Executed Jul 27, disclosed Jul 29, 2 days later.
Over the 21 trading sessions from the disclosed entry session (Jul 29), the stock returned +75.6% (delay-adjusted); from the execution session (Jul 27), +73.4%. Derived: entry at the session's open, exit at the close 20 sessions later.
Carl L Gordon (Director) filed 5 Form 4 reports in the trailing twelve months (5 purchases, 0 sales), most often in Electra Therapeutics, Inc. (ETRA). Across 4 priced purchase filings, the average 21-session return was +17.0% from execution and +14.9% from disclosure (delay-adjusted; derived). The largest single filing was $20.0M of ETRA (1,333,333 sh across 2 lots, as filed), executed Sep 21.
Healthcare · Scribe Therapeutics Inc. is a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→